Ocugen reported a Q4 FY2025 net loss per share of USD 0.06 and a FY2025 net loss per share of USD 0.23. Q4 FY2025 R&D expenses were USD 10.7 million and G&A expenses were USD 6.1 million, while FY2025 R&D expenses were USD 39.8 million and G&A expenses were USD 27.6 million. FY2025 collaborative arrangement revenue was USD 4.4 million, and Q4 collaborative arrangement revenue was no revenue. Cash and restricted cash totaled USD 18.9 million as of December 31, 2025, and Ocugen said January 2026 gross proceeds of USD 22.5 million are expected to fund operations into Q4 2026; if warrants from an August 2025 financing are fully exercised, it expects runway into Q2 2027. On the pipeline, Ocugen said enrollment is complete for the OCU400 Phase 3 liMeliGhT trial in retinitis pigmentosa, with topline Phase 3 data expected in Q1 2027 and a rolling BLA filing targeted for Q3 2026. For OCU410ST in Stargardt disease, the Phase 2/3 pivotal confirmatory trial is nearing enrollment completion, with interim data expected in Q3 2026 and topline Phase 2/3 data expected in Q2 2027 ahead of a planned BLA submission. For OCU410 in geographic atrophy secondary to dry AMD, Ocugen reiterated positive preliminary Phase 2 findings including a 46% lesion growth reduction at 12 months and said full Phase 2 data are expected in March 2026, with plans to initiate Phase 3 in 2026. The company also highlighted a 2025 regional licensing agreement granting Kwangdong Pharmaceutical exclusive Korean rights to OCU400 and noted it created OrthoCellix as a wholly owned subsidiary for its regenerative cell therapy assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603040815PRIMZONEFULLFEED9665630) on March 04, 2026, and is solely responsible for the information contained therein.